Concepedia

Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis

Ji-Min Li, David C.H. Yang, Justin M. Oldham, A. Linderholm, Jun Zhang, Jun Liu, Nicholas J. Kenyon, Ching‐Hsien Chen

Molecular Therapy · 2021 · 47 citations · 29 references

DOIFull text

Open access

Concepts

References

29

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Ting‐Chao Chou, Paul Talalay · Advances in Enzyme Regulation · 1984 · 7.2K citations

, , +16

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis

Julie A. Bjoraker, Jay H. Ryu, Mark Edwin et al. · American Journal of Respiratory and Critical Care Medicine · 1998 · 1K citations

, , +16

Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis

Lutz Wollin, Isabelle Maillet, Valérie Quesniaux et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 626 citations

, , +17

Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44

Yuejuan Li, Dianhua Jiang, Jiurong Liang et al. · The Journal of Experimental Medicine · 2011 · 395 citations · Full text

, , +17

Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis

Xiao Mei Wang, Yingze Zhang, Hong Pyo Kim et al. · The Journal of Experimental Medicine · 2006 · 391 citations · Full text

, , +17